Study in Major Depressive Disorder With BTRX-335140 vs Placebo
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A proof of concept (POC) study evaluating the impact of BTRX-335140 relative to placebo on
symptoms of major depressive disorder (MDD) in adult subjects with MDD and symptoms of
anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17
Scale.